Falconer, D; Papageorgiou, N; Androulakis, E; Alfallouji, Y; Lim, WY; Providencia, R; Tousoulis, D; (2018) Biological therapies targeting arrhythmias: Are cells and genes the answer? [Review]. Expert Opinion on Biological Therapy , 18 (3) pp. 237-249. 10.1080/14712598.2018.1410130.

Preview

Text Bebiano Da Providencia E Costa_Manuscript 30042017.pdf - Accepted Version Download (216kB) | Preview

Abstract

Introduction: Arrhythmias can cause symptoms ranging from simple dizziness to life-threatening circulatory collapse. Current management includes medical therapy and procedures such as catheter ablation or device implantation. However, these strategies still pose a risk of serious side effects, and some patients remain symptomatic. Advancement in our understanding of how arrhythmias develop on the cellular level has made more targeted approaches possible. In addition, contemporary studies have found that several genes are involved in the pathogenesis of arrhythmias. Areas covered: In the present review, the authors explore the cellular and genetic mechanisms leading to arrhythmias as well as the progress that has been made in using both gene and cell therapy to treat tachy- and bradyarrhythmias. They also consider why gene and cell therapy has resulted into a few clinical trials with promising results, however still not applicable in routine clinical practice. Expert opinion: The question currently is whether such biological therapies could replace current established approaches. The contemporary evidence suggests that despite recent advances in this field, it will need more work in experimental models before this is applied into clinical practice. Gene and cell studies targeting conduction and repolarization are promising, but still not ready for use in the clinical setting.

Download activity - last month

Export as XMLJSONCSV

Download activity - last 12 months

Export as XMLJSONCSV

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item